Autolus Therapeutics (AUTL) Income towards Parent Company: 2016-2024

Historic Income towards Parent Company for Autolus Therapeutics (AUTL) over the last 9 years, with Dec 2024 value amounting to -$220.7 million.

  • Autolus Therapeutics' Income towards Parent Company rose 3.63% to -$79.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.8 million, marking a year-over-year increase of 16.81%. This contributed to the annual value of -$220.7 million for FY2024, which is 5.89% down from last year.
  • Latest data reveals that Autolus Therapeutics reported Income towards Parent Company of -$220.7 million as of FY2024, which was down 5.89% from -$208.4 million recorded in FY2023.
  • Autolus Therapeutics' 5-year Income towards Parent Company high stood at -$142.1 million for FY2021, and its period low was -$220.7 million during FY2024.
  • For the 3-year period, Autolus Therapeutics' Income towards Parent Company averaged around -$192.6 million, with its median value being -$208.4 million (2023).
  • In the last 5 years, Autolus Therapeutics' Income towards Parent Company climbed by 24.91% in 2021 and then slumped by 39.98% in 2023.
  • Autolus Therapeutics' Income towards Parent Company (Yearly) stood at -$189.3 million in 2020, then rose by 24.91% to -$142.1 million in 2021, then dropped by 4.73% to -$148.9 million in 2022, then tumbled by 39.98% to -$208.4 million in 2023, then fell by 5.89% to -$220.7 million in 2024.